The decision on lecanemab's funding highlights the stark reality of balancing desperate patient needs against the necessary, cold, hard calculations of cost-effectiveness.
While Lecanemab was celebrated for being the first drug to demonstrate any effect on slowing Alzheimer's, it ultimately does not cure or halt the disease.
[
Collection
]
[
|
...
]